Cargando…
BLOOD-BASED BIOMARKER CHANGES IN A PHASE 2B TRIAL ASSESSING LOMECEL-B IN OLDER ADULTS WITH FRAILTY
Aging frailty (AF) is a multidimensional geriatric syndrome that is characterized by physical and cognitive symptoms, increasing the vulnerability of affected older adults to adverse health outcomes. Mechanistically, a low-grade chronic inflammatory state (inflammaging), endothelial dysfunction, and...
Autores principales: | Ramdas, Kevin, Mehranfard, Danial, Naioti, Eric, Green, Geoff, McClain-Moss, Lisa, Gincel, Dan, Hare, Joshua, Oliva, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766357/ http://dx.doi.org/10.1093/geroni/igac059.2121 |
Ejemplares similares
-
A Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Individuals with Aging Frailty: Study Design and Rationale
por: Ramdas, Kevin, et al.
Publicado: (2021) -
A Phase I Trial Assessing Lomecel-B Infusion in Individuals with Alzheimer’s Disease: Study Design and Rationale
por: Ramdas, Kevin, et al.
Publicado: (2021) -
Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: the ELPIS phase I trial
por: Kaushal, Sunjay, et al.
Publicado: (2023) -
Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease
por: Brody, Mark, et al.
Publicado: (2022) -
Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
por: Oliva, Anthony A., et al.
Publicado: (2019)